Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Identifieur interne : 000D39 ( Main/Exploration ); précédent : 000D38; suivant : 000D40Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
Auteurs : Leena Gandhi [États-Unis] ; Sai-Hong Ignatius Ou [États-Unis] ; Alice T. Shaw [États-Unis] ; Fabrice Barlesi [France] ; Anne-Marie C. Dingemans [Pays-Bas] ; Dong-Wan Kim [Corée du Sud] ; D Ross Camidge [États-Unis] ; Brett G M. Hughes [Australie] ; James C-H Yang [Taïwan] ; Javier De Castro [Espagne] ; Lucio Crino [Italie] ; Hervé Léna [France] ; Pascal Do [France] ; Sophie Golding [Suisse] ; Walter Bordogna [Suisse] ; Ali Zeaiter [Suisse] ; Ahmed Kotb [Suisse] ; Shirish Gadgeel [États-Unis]Source :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antinéoplasiques (usage thérapeutique), Carbazoles (usage thérapeutique), Carcinome pulmonaire non à petites cellules (anatomopathologie), Carcinome pulmonaire non à petites cellules (traitement médicamenteux), Critères d'évaluation de la réponse dans les tumeurs solides, Femelle, Humains, Inhibiteurs de protéines kinases (usage thérapeutique), Jeune adulte, Mâle, Pipéridines (usage thérapeutique), Pyrazoles (usage thérapeutique), Pyridines (usage thérapeutique), Résistance aux médicaments antinéoplasiques, Sujet âgé, Tumeurs du poumon (anatomopathologie), Tumeurs du poumon (traitement médicamenteux), Tumeurs du système nerveux central (secondaire), Tumeurs du système nerveux central (traitement médicamenteux), Études rétrospectives.
- MESH :
- anatomopathologie : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon.
- secondaire : Tumeurs du système nerveux central.
- traitement médicamenteux : Carcinome pulmonaire non à petites cellules, Tumeurs du poumon, Tumeurs du système nerveux central.
- usage thérapeutique : Antinéoplasiques, Carbazoles, Inhibiteurs de protéines kinases, Pipéridines, Pyrazoles, Pyridines.
- Adulte, Adulte d'âge moyen, Critères d'évaluation de la réponse dans les tumeurs solides, Femelle, Humains, Jeune adulte, Mâle, Résistance aux médicaments antinéoplasiques, Sujet âgé, Études rétrospectives.
English descriptors
- KwdEn :
- Adult, Aged, Antineoplastic Agents (therapeutic use), Carbazoles (therapeutic use), Carcinoma, Non-Small-Cell Lung (drug therapy), Carcinoma, Non-Small-Cell Lung (pathology), Central Nervous System Neoplasms (drug therapy), Central Nervous System Neoplasms (secondary), Drug Resistance, Neoplasm, Female, Humans, Lung Neoplasms (drug therapy), Lung Neoplasms (pathology), Male, Middle Aged, Piperidines (therapeutic use), Protein Kinase Inhibitors (therapeutic use), Pyrazoles (therapeutic use), Pyridines (therapeutic use), Response Evaluation Criteria in Solid Tumors, Retrospective Studies, Young Adult.
- MESH :
- chemical , therapeutic use : Antineoplastic Agents, Carbazoles, Piperidines, Protein Kinase Inhibitors, Pyrazoles, Pyridines.
- drug therapy : Carcinoma, Non-Small-Cell Lung, Central Nervous System Neoplasms, Lung Neoplasms.
- pathology : Carcinoma, Non-Small-Cell Lung, Lung Neoplasms.
- secondary : Central Nervous System Neoplasms.
- Adult, Aged, Drug Resistance, Neoplasm, Female, Humans, Male, Middle Aged, Response Evaluation Criteria in Solid Tumors, Retrospective Studies, Young Adult.
Abstract
Central nervous system (CNS) progression is common in patients with anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) receiving crizotinib. Next-generation ALK inhibitors have shown activity against CNS metastases, but accurate assessment of response and progression is vital. Data from two phase II studies in crizotinib-refractory ALK+ NSCLC were pooled to examine the CNS efficacy of alectinib, a CNS-active ALK inhibitor, using Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) and Response Assessment in Neuro-Oncology high-grade glioma (RANO-HGG) criteria.
DOI: 10.1016/j.ejca.2017.05.019
PubMed: 28646771
Affiliations:
- Australie, Corée du Sud, Espagne, France, Italie, Pays-Bas, Suisse, Taïwan, États-Unis
- Basse-Normandie, Californie, Colorado, Communauté de Madrid, Massachusetts, Michigan, Provence-Alpes-Côte d'Azur, Région Bretagne, Région Normandie, Région capitale de Séoul, État de New York
- Caen, Madrid, Marseille, Rennes, Séoul
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000643
- to stream PubMed, to step Curation: 000641
- to stream PubMed, to step Checkpoint: 000641
- to stream Ncbi, to step Merge: 004A36
- to stream Ncbi, to step Curation: 004A36
- to stream Ncbi, to step Checkpoint: 004A36
- to stream Main, to step Merge: 000D34
- to stream Main, to step Curation: 000D39
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.</title><author><name sortKey="Gandhi, Leena" sort="Gandhi, Leena" uniqKey="Gandhi L" first="Leena" last="Gandhi">Leena Gandhi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, New York University, Perlmutter Cancer Center, NYU School of Medicine, New York, USA. Electronic address: leena.gandhi@nyumc.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, New York University, Perlmutter Cancer Center, NYU School of Medicine, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Ou, Sai Hong Ignatius" sort="Ou, Sai Hong Ignatius" uniqKey="Ou S" first="Sai-Hong Ignatius" last="Ou">Sai-Hong Ignatius Ou</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Shaw, Alice T" sort="Shaw, Alice T" uniqKey="Shaw A" first="Alice T" last="Shaw">Alice T. Shaw</name><affiliation wicri:level="2"><nlm:affiliation>Department of Thoracic Oncology, Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Thoracic Oncology, Massachusetts General Hospital, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Barlesi, Fabrice" sort="Barlesi, Fabrice" uniqKey="Barlesi F" first="Fabrice" last="Barlesi">Fabrice Barlesi</name><affiliation wicri:level="3"><nlm:affiliation>Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Dingemans, Anne Marie C" sort="Dingemans, Anne Marie C" uniqKey="Dingemans A" first="Anne-Marie C" last="Dingemans">Anne-Marie C. Dingemans</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht</wicri:regionArea><wicri:noRegion>Maastricht</wicri:noRegion></affiliation></author><author><name sortKey="Kim, Dong Wan" sort="Kim, Dong Wan" uniqKey="Kim D" first="Dong-Wan" last="Kim">Dong-Wan Kim</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Internal Medicine, Seoul National University Hospital, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Camidge, D Ross" sort="Camidge, D Ross" uniqKey="Camidge D" first="D Ross" last="Camidge">D Ross Camidge</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Colorado Cancer Center, Denver, CO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Colorado Cancer Center, Denver, CO</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation></author><author><name sortKey="Hughes, Brett G M" sort="Hughes, Brett G M" uniqKey="Hughes B" first="Brett G M" last="Hughes">Brett G M. Hughes</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, The Prince Charles Hospital, and School of Medicine, University of Queensland, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Oncology, The Prince Charles Hospital, and School of Medicine, University of Queensland, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author><author><name sortKey="Yang, James C H" sort="Yang, James C H" uniqKey="Yang J" first="James C-H" last="Yang">James C-H Yang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="De Castro, Javier" sort="De Castro, Javier" uniqKey="De Castro J" first="Javier" last="De Castro">Javier De Castro</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Medical Oncology Department, Hospital Universitario La Paz, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Crino, Lucio" sort="Crino, Lucio" uniqKey="Crino L" first="Lucio" last="Crino">Lucio Crino</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Istituto Scientifico Romagnolo per lo studio e la Ricerca dei tumori, IRCCS, Meldola, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Oncology, Istituto Scientifico Romagnolo per lo studio e la Ricerca dei tumori, IRCCS, Meldola</wicri:regionArea><wicri:noRegion>Meldola</wicri:noRegion></affiliation></author><author><name sortKey="Lena, Herve" sort="Lena, Herve" uniqKey="Lena H" first="Hervé" last="Léna">Hervé Léna</name><affiliation wicri:level="3"><nlm:affiliation>Pulmonology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pulmonology Department, Centre Hospitalier Universitaire de Rennes, Rennes</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Do, Pascal" sort="Do, Pascal" uniqKey="Do P" first="Pascal" last="Do">Pascal Do</name><affiliation wicri:level="3"><nlm:affiliation>Medical Thoracic Oncology, Centre François Baclesse, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Thoracic Oncology, Centre François Baclesse, Caen</wicri:regionArea><placeName><region type="region">Région Normandie</region><region type="old region">Basse-Normandie</region><settlement type="city">Caen</settlement></placeName></affiliation></author><author><name sortKey="Golding, Sophie" sort="Golding, Sophie" uniqKey="Golding S" first="Sophie" last="Golding">Sophie Golding</name><affiliation wicri:level="1"><nlm:affiliation>Biostatistics Department, F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Biostatistics Department, F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Bordogna, Walter" sort="Bordogna, Walter" uniqKey="Bordogna W" first="Walter" last="Bordogna">Walter Bordogna</name><affiliation wicri:level="1"><nlm:affiliation>Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Zeaiter, Ali" sort="Zeaiter, Ali" uniqKey="Zeaiter A" first="Ali" last="Zeaiter">Ali Zeaiter</name><affiliation wicri:level="1"><nlm:affiliation>Pharmaceutical Division, F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Pharmaceutical Division, F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Kotb, Ahmed" sort="Kotb, Ahmed" uniqKey="Kotb A" first="Ahmed" last="Kotb">Ahmed Kotb</name><affiliation wicri:level="1"><nlm:affiliation>Global Medical Affairs (Oncology), F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Global Medical Affairs (Oncology), F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Gadgeel, Shirish" sort="Gadgeel, Shirish" uniqKey="Gadgeel S" first="Shirish" last="Gadgeel">Shirish Gadgeel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28646771</idno><idno type="pmid">28646771</idno><idno type="doi">10.1016/j.ejca.2017.05.019</idno><idno type="wicri:Area/PubMed/Corpus">000643</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000643</idno><idno type="wicri:Area/PubMed/Curation">000641</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000641</idno><idno type="wicri:Area/PubMed/Checkpoint">000641</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000641</idno><idno type="wicri:Area/Ncbi/Merge">004A36</idno><idno type="wicri:Area/Ncbi/Curation">004A36</idno><idno type="wicri:Area/Ncbi/Checkpoint">004A36</idno><idno type="wicri:Area/Main/Merge">000D34</idno><idno type="wicri:Area/Main/Curation">000D39</idno><idno type="wicri:Area/Main/Exploration">000D39</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.</title><author><name sortKey="Gandhi, Leena" sort="Gandhi, Leena" uniqKey="Gandhi L" first="Leena" last="Gandhi">Leena Gandhi</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, New York University, Perlmutter Cancer Center, NYU School of Medicine, New York, USA. Electronic address: leena.gandhi@nyumc.org.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, New York University, Perlmutter Cancer Center, NYU School of Medicine, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Ou, Sai Hong Ignatius" sort="Ou, Sai Hong Ignatius" uniqKey="Ou S" first="Sai-Hong Ignatius" last="Ou">Sai-Hong Ignatius Ou</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Shaw, Alice T" sort="Shaw, Alice T" uniqKey="Shaw A" first="Alice T" last="Shaw">Alice T. Shaw</name><affiliation wicri:level="2"><nlm:affiliation>Department of Thoracic Oncology, Massachusetts General Hospital, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Thoracic Oncology, Massachusetts General Hospital, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Barlesi, Fabrice" sort="Barlesi, Fabrice" uniqKey="Barlesi F" first="Fabrice" last="Barlesi">Fabrice Barlesi</name><affiliation wicri:level="3"><nlm:affiliation>Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Dingemans, Anne Marie C" sort="Dingemans, Anne Marie C" uniqKey="Dingemans A" first="Anne-Marie C" last="Dingemans">Anne-Marie C. Dingemans</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht</wicri:regionArea><wicri:noRegion>Maastricht</wicri:noRegion></affiliation></author><author><name sortKey="Kim, Dong Wan" sort="Kim, Dong Wan" uniqKey="Kim D" first="Dong-Wan" last="Kim">Dong-Wan Kim</name><affiliation wicri:level="3"><nlm:affiliation>Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.</nlm:affiliation><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>Department of Internal Medicine, Seoul National University Hospital, Seoul</wicri:regionArea><placeName><settlement type="city">Séoul</settlement><region type="capital">Région capitale de Séoul</region></placeName></affiliation></author><author><name sortKey="Camidge, D Ross" sort="Camidge, D Ross" uniqKey="Camidge D" first="D Ross" last="Camidge">D Ross Camidge</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, University of Colorado Cancer Center, Denver, CO, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Colorado Cancer Center, Denver, CO</wicri:regionArea><placeName><region type="state">Colorado</region></placeName></affiliation></author><author><name sortKey="Hughes, Brett G M" sort="Hughes, Brett G M" uniqKey="Hughes B" first="Brett G M" last="Hughes">Brett G M. Hughes</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, The Prince Charles Hospital, and School of Medicine, University of Queensland, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Oncology, The Prince Charles Hospital, and School of Medicine, University of Queensland, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author><author><name sortKey="Yang, James C H" sort="Yang, James C H" uniqKey="Yang J" first="James C-H" last="Yang">James C-H Yang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.</nlm:affiliation><country xml:lang="fr">Taïwan</country><wicri:regionArea>Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei</wicri:regionArea><wicri:noRegion>Taipei</wicri:noRegion></affiliation></author><author><name sortKey="De Castro, Javier" sort="De Castro, Javier" uniqKey="De Castro J" first="Javier" last="De Castro">Javier De Castro</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Medical Oncology Department, Hospital Universitario La Paz, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Crino, Lucio" sort="Crino, Lucio" uniqKey="Crino L" first="Lucio" last="Crino">Lucio Crino</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Istituto Scientifico Romagnolo per lo studio e la Ricerca dei tumori, IRCCS, Meldola, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Oncology, Istituto Scientifico Romagnolo per lo studio e la Ricerca dei tumori, IRCCS, Meldola</wicri:regionArea><wicri:noRegion>Meldola</wicri:noRegion></affiliation></author><author><name sortKey="Lena, Herve" sort="Lena, Herve" uniqKey="Lena H" first="Hervé" last="Léna">Hervé Léna</name><affiliation wicri:level="3"><nlm:affiliation>Pulmonology Department, Centre Hospitalier Universitaire de Rennes, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Pulmonology Department, Centre Hospitalier Universitaire de Rennes, Rennes</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Do, Pascal" sort="Do, Pascal" uniqKey="Do P" first="Pascal" last="Do">Pascal Do</name><affiliation wicri:level="3"><nlm:affiliation>Medical Thoracic Oncology, Centre François Baclesse, Caen, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Medical Thoracic Oncology, Centre François Baclesse, Caen</wicri:regionArea><placeName><region type="region">Région Normandie</region><region type="old region">Basse-Normandie</region><settlement type="city">Caen</settlement></placeName></affiliation></author><author><name sortKey="Golding, Sophie" sort="Golding, Sophie" uniqKey="Golding S" first="Sophie" last="Golding">Sophie Golding</name><affiliation wicri:level="1"><nlm:affiliation>Biostatistics Department, F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Biostatistics Department, F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Bordogna, Walter" sort="Bordogna, Walter" uniqKey="Bordogna W" first="Walter" last="Bordogna">Walter Bordogna</name><affiliation wicri:level="1"><nlm:affiliation>Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Zeaiter, Ali" sort="Zeaiter, Ali" uniqKey="Zeaiter A" first="Ali" last="Zeaiter">Ali Zeaiter</name><affiliation wicri:level="1"><nlm:affiliation>Pharmaceutical Division, F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Pharmaceutical Division, F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Kotb, Ahmed" sort="Kotb, Ahmed" uniqKey="Kotb A" first="Ahmed" last="Kotb">Ahmed Kotb</name><affiliation wicri:level="1"><nlm:affiliation>Global Medical Affairs (Oncology), F. Hoffmann-La Roche Ltd, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Global Medical Affairs (Oncology), F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Gadgeel, Shirish" sort="Gadgeel, Shirish" uniqKey="Gadgeel S" first="Shirish" last="Gadgeel">Shirish Gadgeel</name><affiliation wicri:level="2"><nlm:affiliation>Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antineoplastic Agents (therapeutic use)</term><term>Carbazoles (therapeutic use)</term><term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term><term>Carcinoma, Non-Small-Cell Lung (pathology)</term><term>Central Nervous System Neoplasms (drug therapy)</term><term>Central Nervous System Neoplasms (secondary)</term><term>Drug Resistance, Neoplasm</term><term>Female</term><term>Humans</term><term>Lung Neoplasms (drug therapy)</term><term>Lung Neoplasms (pathology)</term><term>Male</term><term>Middle Aged</term><term>Piperidines (therapeutic use)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Pyrazoles (therapeutic use)</term><term>Pyridines (therapeutic use)</term><term>Response Evaluation Criteria in Solid Tumors</term><term>Retrospective Studies</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Carbazoles (usage thérapeutique)</term><term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term><term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term><term>Critères d'évaluation de la réponse dans les tumeurs solides</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Jeune adulte</term><term>Mâle</term><term>Pipéridines (usage thérapeutique)</term><term>Pyrazoles (usage thérapeutique)</term><term>Pyridines (usage thérapeutique)</term><term>Résistance aux médicaments antinéoplasiques</term><term>Sujet âgé</term><term>Tumeurs du poumon (anatomopathologie)</term><term>Tumeurs du poumon (traitement médicamenteux)</term><term>Tumeurs du système nerveux central (secondaire)</term><term>Tumeurs du système nerveux central (traitement médicamenteux)</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Carbazoles</term><term>Piperidines</term><term>Protein Kinase Inhibitors</term><term>Pyrazoles</term><term>Pyridines</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Central Nervous System Neoplasms</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="secondaire" xml:lang="fr"><term>Tumeurs du système nerveux central</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Central Nervous System Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Tumeurs du poumon</term><term>Tumeurs du système nerveux central</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Carbazoles</term><term>Inhibiteurs de protéines kinases</term><term>Pipéridines</term><term>Pyrazoles</term><term>Pyridines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Drug Resistance, Neoplasm</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Response Evaluation Criteria in Solid Tumors</term><term>Retrospective Studies</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Critères d'évaluation de la réponse dans les tumeurs solides</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Résistance aux médicaments antinéoplasiques</term><term>Sujet âgé</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Central nervous system (CNS) progression is common in patients with anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) receiving crizotinib. Next-generation ALK inhibitors have shown activity against CNS metastases, but accurate assessment of response and progression is vital. Data from two phase II studies in crizotinib-refractory ALK+ NSCLC were pooled to examine the CNS efficacy of alectinib, a CNS-active ALK inhibitor, using Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) and Response Assessment in Neuro-Oncology high-grade glioma (RANO-HGG) criteria.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Corée du Sud</li><li>Espagne</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>Suisse</li><li>Taïwan</li><li>États-Unis</li></country><region><li>Basse-Normandie</li><li>Californie</li><li>Colorado</li><li>Communauté de Madrid</li><li>Massachusetts</li><li>Michigan</li><li>Provence-Alpes-Côte d'Azur</li><li>Région Bretagne</li><li>Région Normandie</li><li>Région capitale de Séoul</li><li>État de New York</li></region><settlement><li>Caen</li><li>Madrid</li><li>Marseille</li><li>Rennes</li><li>Séoul</li></settlement></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Gandhi, Leena" sort="Gandhi, Leena" uniqKey="Gandhi L" first="Leena" last="Gandhi">Leena Gandhi</name></region><name sortKey="Camidge, D Ross" sort="Camidge, D Ross" uniqKey="Camidge D" first="D Ross" last="Camidge">D Ross Camidge</name><name sortKey="Gadgeel, Shirish" sort="Gadgeel, Shirish" uniqKey="Gadgeel S" first="Shirish" last="Gadgeel">Shirish Gadgeel</name><name sortKey="Ou, Sai Hong Ignatius" sort="Ou, Sai Hong Ignatius" uniqKey="Ou S" first="Sai-Hong Ignatius" last="Ou">Sai-Hong Ignatius Ou</name><name sortKey="Shaw, Alice T" sort="Shaw, Alice T" uniqKey="Shaw A" first="Alice T" last="Shaw">Alice T. Shaw</name></country><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Barlesi, Fabrice" sort="Barlesi, Fabrice" uniqKey="Barlesi F" first="Fabrice" last="Barlesi">Fabrice Barlesi</name></region><name sortKey="Do, Pascal" sort="Do, Pascal" uniqKey="Do P" first="Pascal" last="Do">Pascal Do</name><name sortKey="Lena, Herve" sort="Lena, Herve" uniqKey="Lena H" first="Hervé" last="Léna">Hervé Léna</name></country><country name="Pays-Bas"><noRegion><name sortKey="Dingemans, Anne Marie C" sort="Dingemans, Anne Marie C" uniqKey="Dingemans A" first="Anne-Marie C" last="Dingemans">Anne-Marie C. Dingemans</name></noRegion></country><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Kim, Dong Wan" sort="Kim, Dong Wan" uniqKey="Kim D" first="Dong-Wan" last="Kim">Dong-Wan Kim</name></region></country><country name="Australie"><noRegion><name sortKey="Hughes, Brett G M" sort="Hughes, Brett G M" uniqKey="Hughes B" first="Brett G M" last="Hughes">Brett G M. Hughes</name></noRegion></country><country name="Taïwan"><noRegion><name sortKey="Yang, James C H" sort="Yang, James C H" uniqKey="Yang J" first="James C-H" last="Yang">James C-H Yang</name></noRegion></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="De Castro, Javier" sort="De Castro, Javier" uniqKey="De Castro J" first="Javier" last="De Castro">Javier De Castro</name></region></country><country name="Italie"><noRegion><name sortKey="Crino, Lucio" sort="Crino, Lucio" uniqKey="Crino L" first="Lucio" last="Crino">Lucio Crino</name></noRegion></country><country name="Suisse"><noRegion><name sortKey="Golding, Sophie" sort="Golding, Sophie" uniqKey="Golding S" first="Sophie" last="Golding">Sophie Golding</name></noRegion><name sortKey="Bordogna, Walter" sort="Bordogna, Walter" uniqKey="Bordogna W" first="Walter" last="Bordogna">Walter Bordogna</name><name sortKey="Kotb, Ahmed" sort="Kotb, Ahmed" uniqKey="Kotb A" first="Ahmed" last="Kotb">Ahmed Kotb</name><name sortKey="Zeaiter, Ali" sort="Zeaiter, Ali" uniqKey="Zeaiter A" first="Ali" last="Zeaiter">Ali Zeaiter</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D39 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D39 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28646771
|texte= Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28646771" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |